Australia Acne Therapeutics Market Analysis Report 2022 to 2030

Australia Acne Therapeutics Market Analysis

$ 3999

Australia's acne therapeutics market is expected to grow from $120 Mn in 2022 to $226 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-2030. More than 90% of Australian teenagers suffer from acne vulgaris which leads to the increasing demand for acne treatment options in Australia thereby driving the growth of Australia's acne therapeutics market. The market is segmented by treatment, route of administration, age group, and by distribution channel. Some of the major players in the Australian acne therapeutics market are Sypharma, BioDiem, and Novan.

ID: IN10AUPH027 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Parul Choudhary

Buy Now

Australia Acne Therapeutics Market Executive Analysis

Australia's acne therapeutics market is expected to grow from $120 Mn in 2022 to $226 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-30. Australia has set aside $235 Mn for healthcare from 2022 to 2023, of which $100 Mn will be used over the course of two years, to co-create and test novel solutions with states and territories to improve treatment pathways and direct the implementation of the urgent care program. In order to support the recommendations made by the Improving Medicare Taskforce, the government has set aside $750 Mn for the Strengthening Medicare Fund. Other notable health-related aspects of the budget include lower prescription drug costs for Australian households. There will be a reduction in the maximum cost of generic prescription drugs that the Pharmaceutical Benefits Scheme (PBS) will cover. As on January 1, 2023, the $42.50 maximum co-payment will be cut to $30.

More than 90% of Australian teenagers between the ages of 16 and 18 suffer from acne vulgaris. It is typically a self-limiting issue. In this patient population, acne does not naturally heal up for several years. It significantly affects an individual's emotions, psychological condition, and sense of self-worth. Many acne patients in Australia start their therapy with over-the-counter medications. After three months of treatment, patients with mild to moderate acne who do not respond to over-the-counter medications should have a clinical evaluation. Depending on the severity of the acne, conventional acne management uses topical treatment either as monotherapy or in conjunction with systemic medication therapy. Topical and oral retinoids, topical antimicrobials, systemic antibiotics, keratolytics, hormonal therapy, which included oral contraceptives as well as androgen-blocking medications, as well as combination therapy make up the majority of the present array.

australia acne therapeutics market analysis

Market Dynamics

Market Growth Drivers

Growing demand for personal wellness and spot-free skin due to the high psychological burden associated with acne, rising demand for hormonal therapy for acne treatment, and an increase in the development of new acne product lines are some of the main factors driving the Australia acne therapeutics market growth.

Market Restraints

Australia's acne therapeutics market expansion is anticipated to be hampered by harsh side effects around acne-related goods and the introduction of generic acne medications. Furthermore, the spread of the skin positivity movement is limiting the Australia acne therapeutics market expansion.

Competitive Landscape

Key Players

Mayne Pharma (AUS)
Vifor Pharma (AUS)
Sypharma (AUS)
BioDiem (AUS)
Novan
Allergan
Bausch Health
Galderma
Bayer

Healthcare Policies and Regulatory Landscape

The Therapeutic Goods Administration (TGA) is in charge of ensuring the effectiveness, timeliness, and quality of drugs and medical equipment in Australia through the Therapeutic Goods Act 19891 and Therapeutic Goods Regulations. The TGA is best known for its assessment of prescription drugs, but this is merely one of the many tasks it performs. The TGA also handles the regulation of over-the-counter medicines, medical equipment, supplements, and herbal products. Drug regulation is a labor- and resource-intensive procedure. It must take responsibility for the effectiveness, safety, and calibre of the medications made accessible in Australia. The acceptance of a balance between safety and effectiveness is a part of this responsibility. There is no such thing as an entirely risk-free drug, and the approval procedure must take the drug's risk/benefit ratio into account.

Medicare does not always compensate for acne treatments, and coverage is not always assured. Isotretinoin, a potent drug used to treat severe acne, may be covered by Medicare if the condition is severe and persistent and all other treatments have failed. However, this drug can only be obtained with a prescription and can only be given by a dermatologist or other specialized physician. Medicare may also cover other acne treatments, such as specific chemical peels, laser therapy, or other medical procedures, in addition to isotretinoin, but this will also rely on the individual's specific circumstances.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Acne Therapeutics Market Segmentation

By Treatment (Revenue, USD Billion):

Therapeutics
- Retinoid
- Antibiotics
- Hormonal Agents
- Anti-Inflammatory
- Other Agents
- Other Treatments

By Route of Administration (Revenue, USD Billion):

Oral
Topical
Injectable

By Age Group (Revenue, USD Billion):

10 to 17
18 to 44
45 to 64
65 and above

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail and Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.